PBYI PUMA BIOTECHNOLOGY INC revenue, earnings and financials

For the quarter ended June 30, 2026, PUMA BIOTECHNOLOGY INC reported revenue of $56.5M (up 7.8% from a year earlier), net income of $8.19M and diluted EPS of $0.16; over the last four quarters revenue was $231M and net income $26.7M; for the fiscal year ended December 2025 revenue was $228M, down 0.9% on the year before.

PBYI annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $228M, gross profit n/a, operating income $37.3M, net income $31.1M (margin 13.6%), EPS $0.61
• Fiscal year ended Dec 2024: revenue $230M, gross profit n/a, operating income $31.0M, net income $30.3M (margin 13.1%), EPS $0.62
• Fiscal year ended Dec 2023: revenue $236M, gross profit n/a, operating income $32.6M, net income $21.6M (margin 9.2%), EPS $0.45
• Fiscal year ended Dec 2022: revenue $228M, gross profit n/a, operating income $23.7M, net income $2.00K (margin 0.0%), EPS $0.00
• Fiscal year ended Dec 2021: revenue $253M, gross profit n/a, operating income $1.29M, net income $29.1M (margin 11.5%), EPS −$0.72

PBYI quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $56.5M (up 7.8% year over year), net income $8.19M, EPS $0.16
• Quarter ended Mar 31, 2026: revenue $44.8M (down 2.6% year over year), net income −$3.75M, EPS −$0.07
• Quarter ended Dec 31, 2025 (from the annual report): revenue $75.5M (up 27.7% year over year), net income $13.4M, EPS $0.26
• Quarter ended Sep 30, 2025: revenue $54.5M (down 32.4% year over year), net income $8.84M, EPS $0.17
• Quarter ended Jun 30, 2025: revenue $52.4M (up 11.4% year over year), net income $5.86M, EPS $0.12
• Quarter ended Mar 31, 2025: revenue $46.0M (up 5.1% year over year), net income $2.97M, EPS $0.06
• Quarter ended Dec 31, 2024 (from the annual report): revenue $59.1M (down 18.2% year over year), net income $19.3M, EPS $0.40
• Quarter ended Sep 30, 2024: revenue $80.5M (up 43.5% year over year), net income $20.3M, EPS $0.41
• Quarter ended Jun 30, 2024: revenue $47.1M (down 13.7% year over year), net income −$4.53M, EPS −$0.09
• Quarter ended Mar 31, 2024: revenue $43.8M (down 17.1% year over year), net income −$4.82M, EPS −$0.10
• Quarter ended Dec 31, 2023 (from the annual report): revenue $72.2M (up 9.9% year over year), net income $12.3M, EPS $0.25
• Quarter ended Sep 30, 2023: revenue $56.1M (down 1.7% year over year), net income $5.80M, EPS $0.12
• Quarter ended Jun 30, 2023: revenue $54.6M (down 8.3% year over year), net income $2.13M, EPS $0.05
• Quarter ended Mar 31, 2023: revenue $52.8M (up 15.4% year over year), net income $1.40M, EPS $0.03
• Quarter ended Dec 31, 2022 (from the annual report): revenue $65.7M (up 18.6% year over year), net income −$5.61M, EPS −$0.12
• Quarter ended Sep 30, 2022: revenue $57.1M (up 23.5% year over year), net income −$360K, EPS −$0.01
• Quarter ended Jun 30, 2022: revenue $59.5M (up 11.5% year over year), net income $9.37M, EPS $0.21
• Quarter ended Mar 31, 2022: revenue $45.7M (down 53.4% year over year), net income −$3.40M, EPS −$0.08
• Quarter ended Dec 31, 2021 (from the annual report): revenue $55.4M, net income $62.4M, EPS $0.10
• Quarter ended Sep 30, 2021: revenue $46.2M, net income −$44.7M, EPS −$1.09

PBYI cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $41.8M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow $38.9M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow $27.0M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$15.8M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow $20.7M, share buybacks n/a

PBYI balance sheet

• Jun 30, 2026: cash $36.5M, total assets $193M, total liabilities $54.2M, shareholders' equity $139M, long-term debt $0
• Mar 31, 2026: cash $36.2M, total assets $193M, total liabilities $64.3M, shareholders' equity $128M, long-term debt $0
• Dec 31, 2025: cash $29.6M, total assets $216M, total liabilities $86.0M, shareholders' equity $130M, long-term debt $0
• Sep 30, 2025: cash $53.5M, total assets $203M, total liabilities $87.6M, shareholders' equity $115M, long-term debt $0
• Jun 30, 2025: cash $54.7M, total assets $195M, total liabilities $90.2M, shareholders' equity $105M, long-term debt $10.9M
• Mar 31, 2025: cash $63.0M, total assets $196M, total liabilities $99.1M, shareholders' equity $97.1M, long-term debt $10.6M
• Dec 31, 2024: cash $69.2M, total assets $213M, total liabilities $121M, shareholders' equity $92.1M, long-term debt $21.7M
• Sep 30, 2024: cash $67.3M, total assets $221M, total liabilities $150M, shareholders' equity $71.1M, long-term debt $32.7M

What is PBYI's revenue?

PUMA BIOTECHNOLOGY INC reported $231M of revenue over its last four quarters, through June 30, 2026.

Is PBYI profitable?

Yes. PUMA BIOTECHNOLOGY INC earned $26.7M over the last four quarters.

What is PBYI's EPS?

Diluted earnings per share over the last four quarters were $0.52; $0.16 in the latest quarter.

PBYI ownership and insider trades · All stocks